Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Steven D. Podos"'
Autor:
Xuan Yuan, Eleni Gavriilaki, Jane A. Thanassi, Guangwei Yang, Andrea C. Baines, Steven D. Podos, Yongqing Huang, Mingjun Huang, Robert A. Brodsky
Publikováno v:
Haematologica, Vol 102, Iss 3 (2017)
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement co
Externí odkaz:
https://doaj.org/article/076079ff9a2e4756996fe44833d94790
Autor:
Steven D. Podos, Howard Trachtman, Gerald B. Appel, Andrew S. Bomback, Bradley P. Dixon, Jack F.M. Wetzels, H. Terence Cook, Samir V. Parikh, Matthew C. Pickering, James Tumlin, Craig B. Langman, Liz Lightstone, C. John Sperati, Erica Daina, Koenraad Peter Bouman, Kara Rice, Jane A. Thanassi, Mingjun Huang, Carla Nester, Giuseppe Remuzzi
Publikováno v:
American Journal of Nephrology. 53:675-686
Introduction: C3 glomerulopathy (C3G) is a rare, progressive kidney disease resulting from dysregulation of the alternative pathway (AP) of complement. Biomarkers at baseline were investigated in patients with C3G who participated in two phase 2 stud
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6033149cda007f887e49f8c0ccd572ac
https://doi.org/10.1159/000527166
https://doi.org/10.1159/000527166
Autor:
Carla Nester, Gerald B. Appel, Andrew S. Bomback, Koenraad Peter Bouman, H. Terence Cook, Erica Daina, Bradley P. Dixon, Kara Rice, Nader Najafian, James Hui, Steven D. Podos, Craig B. Langman, Liz Lightstone, Samir V. Parikh, Matthew C. Pickering, C. John Sperati, Howard Trachtman, James Tumlin, Aiko PJ de Vries, Jack F.M. Wetzels, Giuseppe Remuzzi
Publikováno v:
American Journal of Nephrology, 53(10), 687-700. KARGER
Introduction: C3 glomerulopathy (C3G) is an ultrarare, chronic and progressive nephropathy mediated by dysregulation of the alternative pathway of complement (AP), with poor prognosis and limited treatment options. Targeted inhibition of proximal AP
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc2a943827d901f4df59681d16fd4a57
https://pubmed.ncbi.nlm.nih.gov/36423588
https://pubmed.ncbi.nlm.nih.gov/36423588
Autor:
David D, Boyer, Ya-Ping, Ko, Steven D, Podos, Mark E, Cartwright, Xiang, Gao, Jason A, Wiles, Mingjun, Huang
Publikováno v:
Translational Vision Science & Technology. 11:37
Complement alternative pathway (AP) dysregulation has been implicated in geographic atrophy, an advanced form of age-related macular degeneration. Danicopan is an investigational, first-in-class inhibitor of factor D, an essential AP activation enzym
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7bda3565e346b82afe4f5474a0ec5ed
https://doi.org/10.1167/tvst.11.10.37
https://doi.org/10.1167/tvst.11.10.37
Autor:
Gerald B. Appel, Jack F.M. Wetzels, Mingjun Huang, Steven D. Podos, Jane A. Thanassi, Kara Rice, John Sperati, Giuseppe Remuzzi, Carla M. Nester, Craig B. Langman, Samir M. Parikh, Erica Daina, Jonathan J. Hogan, Bradley P. Dixon, Andrew S. Bomback, Koen Bouman, Liz Lightstone, James A. Tumlin, Howard Trachtman, Matthew C. Pickering, Terry Cook
Publikováno v:
Nephrology Dialysis Transplantation. 36
Background and Aims C3 glomerulopathy (C3G) and immune complex membranoproliferative glomerulonephritis (IC-MPGN) are rare, progressive kidney diseases requiring a biopsy for definite diagnosis. Both C3G and IC-MPGN are attributed to complement dysre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4557f7c9ba95546ad3f8b89176d635dd
https://doi.org/10.1093/ndt/gfab092.004
https://doi.org/10.1093/ndt/gfab092.004
Autor:
Robert A. Brodsky, Steven D. Podos, Jane A. Thanassi, Eleni Gavriilaki, Xuan Yuan, Guangwei Yang, Yongqing Huang, Andrea C. Baines, Mingjun Huang
Publikováno v:
Haematologica
Paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome are diseases of excess activation of the alternative pathway of complement that are treated with eculizumab, a humanized monoclonal antibody against the terminal complement co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d56db03dbb05852065431e12cf751f8d
http://europepmc.org/articles/PMC5394948
http://europepmc.org/articles/PMC5394948
Factor D is a serine protease (SP) consisting of a single polypeptide of 228 amino acids. Unlike other SPs in the complement system, factor D circulates in the plasma as a mature but ‘resting-state’ form at a very low concentration and is produce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7590f42650955686cb953490bcd3298
https://doi.org/10.1016/b978-0-12-810420-0.00012-2
https://doi.org/10.1016/b978-0-12-810420-0.00012-2
Comparison of two commercial enzyme-linked immunosorbent assays for detection of complement factor D
Autor:
Dharaben Patel, Amanda Luu, Manuel Galvan, Guangwei Yang, Yongsen Zhao, Jane A. Thanassi, Mingjun Huang, Wengang Yang, Steven D. Podos
Publikováno v:
Molecular Immunology. 102:199-200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::de0571ef57b5affd3ee3bf6f6dd68900
https://doi.org/10.1016/j.molimm.2018.06.181
https://doi.org/10.1016/j.molimm.2018.06.181
Autor:
Jane A. Thanassi, Dharaben Patel, Guangwei Yang, Steven D. Podos, Manuel Galvan, Yongsen Zhao, Mingjun Huang, Wengang Yang, Amanda Luu
Publikováno v:
Molecular Immunology. 102:219-220
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48ce313fda4e231b49daada2b06b3204
https://doi.org/10.1016/j.molimm.2018.06.226
https://doi.org/10.1016/j.molimm.2018.06.226
Publikováno v:
Blood. 134:5763-5763
Introduction: Treatment of complement-associated disorders with the terminal complement inhibitor eculizumab brings a thousand-fold elevated risk of meningococcal disease due to blockage of serum bactericidal activity (SBA) and opsonophagocytosis aga
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34cf5b4ac891feac06da6598403ff658
https://doi.org/10.1182/blood-2019-132253
https://doi.org/10.1182/blood-2019-132253